Our findings explain one of the molecular mechanisms of FXR1’s reported tumorigenic role in HNSCC and lay the groundwork for future research into how targeting the interface between FXR1 and PRMT5 can affect gene expression and aid in the development of novel therapies. This evidence concerns the gene FXR1 and head and neck squamous cell carcinoma.